Literature DB >> 10226049

Redox metals and neurodegenerative disease.

L M Sayre1, G Perry, M A Smith.   

Abstract

Multiple lines of evidence implicate redox-active transition metals as mediators of oxidative stress in neurodegenerative diseases. Among the recent research discoveries is the finding that transition metals bind to proteins associated with neurodegeneration, including the prion protein. Whereas binding in the latter case may serve an antioxidant function, adventitious binding of metals to other proteins appears to preserve their catalytic redox activity in a manner that disturbs free radical homeostasis. Alterations in the levels of copper- and iron-containing metalloenzymes, involved in processing partially reduced oxygen species, are also likely to contribute to altered redox balance in neurodegenerative diseases. Nonetheless, even in familial forms of amyotrophic lateral sclerosis linked to mutations in superoxide dismutase, it is unclear whether an altered enzyme activity or, indirectly, a disturbance in transition-metal homeostasis is involved in the disease pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10226049     DOI: 10.1016/S1367-5931(99)80035-0

Source DB:  PubMed          Journal:  Curr Opin Chem Biol        ISSN: 1367-5931            Impact factor:   8.822


  35 in total

Review 1.  Methylmercury: recent advances in the understanding of its neurotoxicity.

Authors:  Michael Aschner; Tore Syversen
Journal:  Ther Drug Monit       Date:  2005-06       Impact factor: 3.681

2.  The role of trace elements in the pathogenesis and progress of pilocarpine-induced epileptic seizures.

Authors:  J Chwiej; W Winiarski; M Ciarach; K Janeczko; M Lankosz; K Rickers; Z Setkowicz
Journal:  J Biol Inorg Chem       Date:  2008-08-08       Impact factor: 3.358

3.  Nanoparticle and iron chelators as a potential novel Alzheimer therapy.

Authors:  Gang Liu; Ping Men; George Perry; Mark A Smith
Journal:  Methods Mol Biol       Date:  2010

4.  Association of serum trace elements and minerals with genetic generalized epilepsy and idiopathic intractable epilepsy.

Authors:  D K V Prasad; Uzma Shaheen; U Satyanarayana; T Surya Prabha; A Jyothy; Anjana Munshi
Journal:  Neurochem Res       Date:  2014-09-26       Impact factor: 3.996

5.  Dual-probe (colorimetric and fluorometric) detection of ferritin using antibody-modified gold@carbon dot nanoconjugates.

Authors:  Eepsita Priyadarshini; Kamla Rawat; Himadri B Bohidar; Paulraj Rajamani
Journal:  Mikrochim Acta       Date:  2019-10-09       Impact factor: 5.833

Review 6.  Alzheimer's disease: cerebrovascular dysfunction, oxidative stress, and advanced clinical therapies.

Authors:  Michael W Marlatt; Paul J Lucassen; George Perry; Mark A Smith; Xiongwei Zhu
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

7.  Abnormal iron metabolism in fibroblasts from a patient with the neurodegenerative disease hereditary ferritinopathy.

Authors:  Ana G Barbeito; Thierry Levade; Marie B Delisle; Bernardino Ghetti; Ruben Vidal
Journal:  Mol Neurodegener       Date:  2010-11-10       Impact factor: 14.195

8.  Metal chelators coupled with nanoparticles as potential therapeutic agents for Alzheimer's disease.

Authors:  Gang Liu; Ping Men; George Perry; Mark A Smith
Journal:  J Nanoneurosci       Date:  2009-06-01

Review 9.  Neurodegenerative disorders and nanoformulated drug development.

Authors:  Ari Nowacek; Lisa M Kosloski; Howard E Gendelman
Journal:  Nanomedicine (Lond)       Date:  2009-07       Impact factor: 5.307

10.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.